Is Pazopanib Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Pazopanib? Is Pazopanib safe for nursing mother and child? Does Pazopanib extracts into breast milk? Does Pazopanib has any long term or short term side effects on infants? Can Pazopanib influence milk supply or can Pazopanib decrease milk supply in lactating mothers?

• DrLact safety Score for Pazopanib is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Pazopanib may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Pazopanib may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Pazopanib .
• It is recommended to evaluate the advantage of not breastfeeding while using Pazopanib Vs not using Pazopanib And continue breastfeeding.
• While using Pazopanib Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of several neoplastic diseases. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½). It means that 13 days should be waited before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

No information is available on the clinical use of pazopanib during breastfeeding. Because pazopanib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 31 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during pazopanib therapy and for 2 weeks after the final dose.